Fischer SM, Klenske E, Schmitt H, Vitali F, Hirschmann S, Koch F, Ramming A, Zundler S, Nagore D, Uter W, Neurath M, Atreya R (2018)
Publication Type: Conference contribution
Publication year: 2018
Book Volume: 12
Pages Range: S416-S416
DOI: 10.1093/ecco-jcc/jjx180.734
APA:
Fischer, S.M., Klenske, E., Schmitt, H., Vitali, F., Hirschmann, S., Koch, F.,... Atreya, R. (2018). Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients. (pp. S416-S416).
MLA:
Fischer, Sven Moritz, et al. "Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients." 2018. S416-S416.
BibTeX: Download